RxDoctor Payments Data

Amanda Hughes, PA

Physician Assistant · Sicklerville, NJNPI 1457900599

Payments from drug & device makers

$2,152in general payments, 2019–2025

Across 100 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$724
  • AstraZeneca$245
  • AbbVie$162
  • Amgen$131
  • Kowa Pharmaceuticals America, Inc.$128
  • Idorsia Pharmaceuticals US Inc$117
  • plus $644 from 15 others

What the payments were for

  • Food & beverage$2,12099%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,152 in reported general payments places this provider in the 85th percentile of 2,726 physician assistant providers in New Jersey.

See all physician assistant providers in New Jersey

Medicare billing

Part B allowed, 2024
$54,450
Medicare patients
243
Services billed
628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$77,161
JardianceEmpagliflozin41$66,953
MounjaroTirzepatide28$45,705
EliquisApixaban50$43,880
JanuviaSitagliptin Phosphate25$35,314
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$35,089
TrulicityDulaglutide15$31,533
FarxigaDapagliflozin Propanediol18$23,529
XareltoRivaroxaban13$20,938
TradjentaLinagliptin12$17,292
Atorvastatin Calcium298$3,551
Albuterol Sulfate HfaAlbuterol Sulfate145$3,542
Rosuvastatin Calcium231$3,387
Diclofenac Sodium23$2,950
Levothyroxine Sodium219$1,954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$64$84,24553 claims
Lilly USA, LLCMounjaro, Trulicity$54$77,23843 claims
Novo NordiskOzempic$724$77,16142 claims
PfizerEliquis$45$43,88050 claims
MerckJanuvia$28$35,31425 claims
GSKTrelegy Ellipta$97$35,08930 claims
AstraZenecaFarxiga$245$23,52918 claims
Johnson & JohnsonXarelto$15$20,93813 claims
AbbVieSynthroid$162$1,21523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,726 physician assistant providers in New Jersey.

Other physician assistant in Sicklerville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →